Combination Therapy in Pulmonary Arterial Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

August 31, 2010

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Bosentan

Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated

DRUG

Sildenafil

Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY